Table 1.
Clinical characteristics of patients included in the study
| Characteristics | Overall (N = 90) | Bologna (N = 50) | Wrocław (N = 13) | Verona (N = 15) | Rome (N = 5) | Pavia (N = 7) |
|---|---|---|---|---|---|---|
| Age at allo-HSCT, y (± SD) | 9.0 ± 5.5 | 10.0 ± 5.6 | 7.2 ± 4.1 | 8.0 ± 5.3 | 8.8 ± 7.9 | 8.1 ± 6.3 |
| Male sex, n (%) | 53 (59) | 29 (58) | 11 (85) | 6 (40) | 1 (20) | 6 (86) |
| Disease, n (%) | ||||||
| Acute lymphoblastic leukemia | 33 (37) | 19 (38) | 5 (38) | 6 (40) | 3 (60) | 0 (0) |
| Acute myeloid leukemia | 19 (21) | 14 (28) | 0 (0) | 2 (13) | 1 (20) | 2 (29) |
| Non-Hodgkin lymphoma | 2 (2) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| MDS or JMML | 10 (11) | 7 (14) | 2 (15) | 1 (7) | 0 (0) | 0 (0) |
| Nonmalignant disease | 26 (29) | 8 (16) | 6 (49) | 6 (40) | 1 (20) | 5 (71) |
| Type of donor (%) | ||||||
| Unrelated | 55 (61) | 30 (60) | 8 (62) | 13 (87) | 1 (20) | 3 (43) |
| HLA-haploidentical relative | 18 (20) | 10 (20) | 2 (15) | 0 (0) | 3 (60) | 3 (43) |
| Identical sibling | 17 (19) | 10 (20) | 3 (23) | 2 (13) | 1 (20) | 1 (14) |
| Stem cell source (%) | ||||||
| Bone marrow | 68 (76) | 47 (94) | 5 (38) | 10 (67) | 2 (49) | 4 (57) |
| PBSC | 21 (23) | 3 (6) | 8 (62) | 4 (27) | 3 (60) | 3 (43) |
| Cord blood | 1 (1) | 0 (0) | 0 (0) | 1 (7) | 0 (0) | 0 (0) |
| Intensity of conditioning (%) | ||||||
| Ablative | 83 (92) | 49 (98) | 10 (77) | 12 (80) | 5 (100) | 7 (100) |
| Reduced intensity | 7 (8) | 1 (2) | 3 (23) | 3 (20) | 0 (0) | 0 (0) |
| Follow-up of survivors, mo | ||||||
| Median | 52.4 | 55.4 | 23 | 39.2 | 78.5 | 79.4 |
| Interquartile range | 26.3-79.0 | 24.0-78.5 | 22.8-24.0 | 24.0-33.0 | 78.0-79.0 | 78.5-80.0 |
JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cell; SD, standard deviation.